Evolving Management of Hip Fracture Patients on Anticoagulant and Antiplatelet Medications: A 22-Year Cohort Study

OBJECTIVES: To evaluate temporal trends in anticoagulant (AC) and antiplatelet (AP) use among patients undergoing operative treatment of hip fractures and to assess the association of antithrombotic regimen with time to surgery and postoperative outcomes. METHODS: Design: Retrospective cohort study. SETTING: Single North American Level I trauma center. PATIENT SELECTION CRITERIA: Patients aged 55 years or older who underwent operative treatment for a hip fracture (AO/OTA types 31-A, 31-B, and 31-C) between 2000 and 2022 while receiving anticoagulant and/or antiplatelet therapy at admission were included. OUTCOME MEASURES AND COMPARISONS: Temporal trends in antithrombotic prescribing, time to surgery, perioperative transfusion, readmission, 90-day medical and surgical postoperative complications, and 90-day mortality were assessed. The odds of warfarin versus direct oral anticoagulant (DOAC) prescription were compared across study years, and time to surgery from admission and each outcome were compared across study years and across antithrombotic regimens (warfarin, DOAC, DOAC or warfarin plus antiplatelet, and antiplatelet alone). RESULTS: 476 patients were included (mean age 81.2 years [range, 60-103]; 288 [60.4%] female). Anticoagulant therapy was used by 155 (32.7%) and antiplatelet therapy by 385 (80.7%); 64 (13.4%) received both. The odds of warfarin prescription relative to a DOAC decreased by an estimated 37% per year (odds ratio [OR] 0.63, 95% CI 0.53-0.74; P<0.001). Time to surgery did not change significantly over the study period (-0.01 hours/year, 95% CI -0.04 to 0.02; P=0.4) and was not associated with antithrombotic regimen (-0.01, 95% CI: -0.04-0.01; P=0.3). Perioperative transfusion odds decreased 12% per year (OR 0.88, 95% CI 0.84-0.93; P<0.001) and 1-year readmission odds decreased 46% per year (OR 0.54, 95% CI 0.48-0.60; P<0.001), independent of medication class. Ninety-day (OR 0.99, 95% CI 0.95-1.04; P=0.8) and 90-day mortality (OR 0.79, 95% CI 0.54-1.14; P=0.2) did not change over time. CONCLUSIONS: In this 22-year single-center cohort of hip-fracture patients receiving anticoagulant (AC) or antiplatelet (AP) therapy, antithrombotic regimen was not associated with time to surgery, 90-day complications, or mortality. Perioperative transfusion and 1-year readmission rates declined over the study period independent of medication class. These findings supported expedited operative management of hip fractures in patients receiving AC or AP therapy. LEVEL OF EVIDENCE: III.

Authors

Institutions

Publication Details

Journal
Journal of Orthopaedic Trauma
Published
2026-11-16
DOI
https://doi.org/10.1097/bot.0000000000003314
Primary Topic
Hip and Femur Fractures
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evolving Management of Hip Fracture Patients on Anticoagulant and Antiplatelet Medications: A 22-Year Cohort Study

Joseph Cohen, Hanna E. House, Insup Hong, Hobie D. Summers et al.
1 links
Journal of Orthopaedic Trauma
Hip and Femur Fractures
article

Evolving Management of Hip Fracture Patients on Anticoagulant and Antiplatelet Medications: A 22-Year Cohort Study

Joseph Cohen, Hanna E. House, Insup Hong, Hobie D. Summers, Ashley E. Levack, Michelle Shimizu, Austin Schwartz
article en

Abstract

OBJECTIVES: To evaluate temporal trends in anticoagulant (AC) and antiplatelet (AP) use among patients undergoing operative treatment of hip fractures and to assess the association of antithrombotic regimen with time to surgery and postoperative outcomes. METHODS: Design: Retrospective cohort study. SETTING: Single North American Level I trauma center. PATIENT SELECTION CRITERIA: Patients aged 55 years or older who underwent operative treatment for a hip fracture (AO/OTA types 31-A, 31-B, and 31-C) between 2000 and 2022 while receiving anticoagulant and/or antiplatelet therapy at admission were included. OUTCOME MEASURES AND COMPARISONS: Temporal trends in antithrombotic prescribing, time to surgery, perioperative transfusion, readmission, 90-day medical and surgical postoperative complications, and 90-day mortality were assessed. The odds of warfarin versus direct oral anticoagulant (DOAC) prescription were compared across study years, and time to surgery from admission and each outcome were compared across study years and across antithrombotic regimens (warfarin, DOAC, DOAC or warfarin plus antiplatelet, and antiplatelet alone). RESULTS: 476 patients were included (mean age 81.2 years [range, 60-103]; 288 [60.4%] female). Anticoagulant therapy was used by 155 (32.7%) and antiplatelet therapy by 385 (80.7%); 64 (13.4%) received both. The odds of warfarin prescription relative to a DOAC decreased by an estimated 37% per year (odds ratio [OR] 0.63, 95% CI 0.53-0.74; P<0.001). Time to surgery did not change significantly over the study period (-0.01 hours/year, 95% CI -0.04 to 0.02; P=0.4) and was not associated with antithrombotic regimen (-0.01, 95% CI: -0.04-0.01; P=0.3). Perioperative transfusion odds decreased 12% per year (OR 0.88, 95% CI 0.84-0.93; P<0.001) and 1-year readmission odds decreased 46% per year (OR 0.54, 95% CI 0.48-0.60; P<0.001), independent of medication class. Ninety-day (OR 0.99, 95% CI 0.95-1.04; P=0.8) and 90-day mortality (OR 0.79, 95% CI 0.54-1.14; P=0.2) did not change over time. CONCLUSIONS: In this 22-year single-center cohort of hip-fracture patients receiving anticoagulant (AC) or antiplatelet (AP) therapy, antithrombotic regimen was not associated with time to surgery, 90-day complications, or mortality. Perioperative transfusion and 1-year readmission rates declined over the study period independent of medication class. These findings supported expedited operative management of hip fractures in patients receiving AC or AP therapy. LEVEL OF EVIDENCE: III.

Journal of Orthopaedic Trauma
Loyola University Medical Center (US), Loyola University Chicago (US), Loyola Medicine (US)
Good health and well-being
Hip and Femur Fractures
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon